<DOC>
	<DOCNO>NCT01297699</DOCNO>
	<brief_summary>The purpose investigate tocilizumab administration patient moderately severely sight-threatening GO ( Graves ' ophthalmopathy ) without response treatment corticoid intravenous pulse . Currently , patient surgery therapeutic alternative . The principal aim study evaluate efficacy safety tocilizumab treatment order provide good alternative surgery patient .</brief_summary>
	<brief_title>Tocilizumab Treatment Graves´ Ophthalmopathy ( Graves´ Orbitopathy Thyroid Eye Disease )</brief_title>
	<detailed_description>Thyroid orbitopathy Graves´orbitopathy ( GO ) manifest inflammation orbital periorbital soft tissue . Ten percent patient GO long-term serious eye problem . The cause GO complex . Autoreactive T cell recognize autoantigen , TSH receptor present orbit thyroid follicular cell , secrete cytokine ( IL-6 ) , stimulate fibroblast synthesize glycosaminoglycan , draws liquid produce periorbital edema muscle , cause exophthalmos . This approach suggest inhibition IL-6 effective treatment problem basis tocilizumab specifically bind receptor IL-6 , soluble membrane-bound . Tocilizumab show inhibit signal mediate IL-6Rm IL-6Rs .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<criteria>Principal Patients diagnose GO CAS ≥ 4 index severity , accord EUGOGO guideline , 1. moderately severely 2. sightthreatening GO , receive corticosteroid pulse treatment due : Poor response intravenous corticosteroid pulse Or Recurrence GO , treatment intravenous corticosteroid Orbital decompression surgery need immediately Active smoker Patients could need treatment radioactive iodine thyroidectomy study Pregnant patient patient plan become pregnant study History chronic recurrent active infection History intestinal ulceration diverticulitis Patients history chronic liver disease liver disorder : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 5 time upper limit normal ( ULN ) History HIV , hepatitis C hepatitis B Positive Neutrophil count &lt; 0.5 × 109/L platelet count &lt; 50×103/μL Simultaneous use contraindication use immunosuppressive agent A treatment another investigational drug within four week selection five halflives study drug Cardiovascular cerebrovascular disease clinically significant Uncontrolled diabetes mellitus Use corticosteroid four week inclusion period History reaction anaphylactic allergic severe human monoclonal antibody , humanize murine Uncontrolled pathology , whose exacerbation treat corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Graves´ orbitopathy</keyword>
	<keyword>Graves´ ophthalmopathy</keyword>
	<keyword>Thyroid eye disease</keyword>
	<keyword>Thyroid-associated ophthalmopathy</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>EUGOGO</keyword>
	<keyword>CAS</keyword>
</DOC>